US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
Highlights:
MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) — Immuron Limited (ASX:IMC; NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide shareholders and the market with a progress update on the US Department of Defense Uniformed Services University (USU) Clinical Evaluation of Travelan.
Related news for (IMRN)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/17/25 06:00 AM
- 24/7 Market News Snapshot 17 July, 2025 – Immuron Limited American Depositary Shares (NASDAQ:IMRN)
- immuron announces new u.s. department of defense research award for naval medical research command and walter reed army institute of research to advance travelan®
- Immuron Moving to Phase 3 Clinical Trials following Positive Travelan Results
- Immuron CEO, Steven Lydeamore Investor Webinar Presentation